

DYNAVAX TECHNOLOGIES CORPORATION

**VRBPAC Meeting
 28 July 2017**

**Errata to the Sponsor Briefing Document
 BLA # 125428 (HEPLISAV-B™)**

On Page 94, Table 16-4, *Listing of Subjects with Bell's Palsy by Days Since Last Active Dose (Primary Safety Population)* should be updated to include 2 additional rows:

Table 6-14: Listing of Subjects with Bell's Palsy by Days Since Last Active Dose (Primary Safety Population)

Trial	Treatment Assignment	Age (y)	Sex	Last Active Dose	Days Since Last Active Dose	Severity	Outcome
HBV-23	HEPLISAV	49	M	1	10	1	Resolved
HBV-23	Engerix-B	29	M	3	27	4	Resolved
HBV-23	HEPLISAV	49	F	2	0 ^a (55)	2	Resolved
HBV-10	Engerix-B	34	M	2	122	2	Resolved
HBV-23	HEPLISAV	31	F	2	170	3	Resolved
HBV-23	HEPLISAV	49	M	2	172	3	Ongoing
HBV-23	HEPLISAV	52	M	2	256	3	Resolved
HBV-16	HEPLISAV	59	M	2	271	1	Resolved

F = female; M = male; y = years.

^a Event occurred approximately 12-18 hours after the subject received the second dose of study vaccine and 55 days after the first dose.

Note: Severity: 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Life-threatening or disabling; 5 = Death.